<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">32314027</PMID><DateCompleted><Year>2021</Year><Month>05</Month><Day>14</Day></DateCompleted><DateRevised><Year>2021</Year><Month>05</Month><Day>14</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1619-7089</ISSN><JournalIssue CitedMedium="Internet"><Volume>47</Volume><Issue>11</Issue><PubDate><Year>2020</Year><Month>Oct</Month></PubDate></JournalIssue><Title>European journal of nuclear medicine and molecular imaging</Title><ISOAbbreviation>Eur J Nucl Med Mol Imaging</ISOAbbreviation></Journal><ArticleTitle>Combined brain and spinal FDG PET allows differentiation between ALS and ALS mimics.</ArticleTitle><Pagination><StartPage>2681</StartPage><EndPage>2690</EndPage><MedlinePgn>2681-2690</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00259-020-04786-y</ELocationID><Abstract><AbstractText Label="PURPOSE">Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder with on average a 1-year delay between symptom onset and diagnosis. Studies have demonstrated the value of [<sup>18</sup>F]-FDG PET as a sensitive diagnostic biomarker, but the discriminatory potential to differentiate ALS from patients with symptoms mimicking ALS has not been investigated. We investigated the combination of brain and spine [<sup>18</sup>F]-FDG PET-CT for differential diagnosis between ALS and ALS mimics in a real-life clinical diagnostic setting.</AbstractText><AbstractText Label="METHODS">Patients with a suspected diagnosis of ALS (n&#x2009;=&#x2009;98; 64.8&#x2009;&#xb1;&#x2009;11&#xa0;years; 61&#xa0;M) underwent brain and spine [<sup>18</sup>F]-FDG PET-CT scans. In 62 patients, ALS diagnosis was confirmed (67.8&#x2009;&#xb1;&#x2009;10&#xa0;years; 35&#xa0;M) after longitudinal follow-up (average 18.1&#x2009;&#xb1;&#x2009;8.4&#xa0;months). In 23 patients, another disease was diagnosed (ALS mimics, 60.9&#x2009;&#xb1;&#x2009;12.9&#xa0;years; 17&#xa0;M) and 13 had a variant motor neuron disease, primary lateral sclerosis (PLS; n&#x2009;=&#x2009;4; 53.6&#x2009;&#xb1;&#x2009;2.5&#xa0;years; 2&#xa0;M) and progressive muscular atrophy (PMA; n&#x2009;=&#x2009;9; 58.4&#x2009;&#xb1;&#x2009;7.3&#xa0;years; 7&#xa0;M). Spine metabolism was determined after manual and automated segmentation. VOI- and voxel-based comparisons were performed. Moreover, a support vector machine (SVM) approach was applied to investigate the discriminative power of regional brain metabolism, spine metabolism and the combination of both.</AbstractText><AbstractText Label="RESULTS">Brain metabolism was very similar between ALS mimics and ALS, whereas cervical and thoracic spine metabolism was significantly different (in standardised uptake values; cervical: ALS 2.1&#x2009;&#xb1;&#x2009;0.5, ALS mimics 1.9&#x2009;&#xb1;&#x2009;0.4; thoracic: ALS 1.8&#x2009;&#xb1;&#x2009;0.3, ALS mimics 1.5&#x2009;&#xb1;&#x2009;0.3). As both brain and spine metabolisms were very similar between ALS mimics and PLS/PMA, groups were pooled for accuracy analyses. Mean discrimination accuracy was 65.4%, 80.0% and 81.5%, using only brain metabolism, using spine metabolism and using both, respectively.</AbstractText><AbstractText Label="CONCLUSION">The combination of brain and spine FDG PET-CT with SVM classification is useful as discriminative biomarker between ALS and ALS mimics in a real-life clinical setting.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Van Weehaeghe</LastName><ForeName>Donatienne</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Nuclear Medicine and Molecular Imaging, Department of Imaging and Pathology, KU Leuven, Leuven, Belgium. donatienne.vanweehaeghe@uzleuven.be.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Nuclear Medicine, UZ Leuven, Herestraat 49, 3000, Leuven, Belgium. donatienne.vanweehaeghe@uzleuven.be.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Devrome</LastName><ForeName>Martijn</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Nuclear Medicine and Molecular Imaging, Department of Imaging and Pathology, KU Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schramm</LastName><ForeName>Georg</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Nuclear Medicine and Molecular Imaging, Department of Imaging and Pathology, KU Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Vocht</LastName><ForeName>Joke</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, University Hospital Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deckers</LastName><ForeName>Wies</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Division of Nuclear Medicine, UZ Leuven, Herestraat 49, 3000, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baete</LastName><ForeName>Kristof</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Nuclear Medicine and Molecular Imaging, Department of Imaging and Pathology, KU Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Nuclear Medicine, UZ Leuven, Herestraat 49, 3000, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Damme</LastName><ForeName>Philip</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Neurology, University Hospital Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratory of Neurobiology, Center for Brain &amp; Disease Research, VIB and KU Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Koole</LastName><ForeName>Michel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Nuclear Medicine and Molecular Imaging, Department of Imaging and Pathology, KU Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Van Laere</LastName><ForeName>Koen</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Nuclear Medicine and Molecular Imaging, Department of Imaging and Pathology, KU Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Nuclear Medicine, UZ Leuven, Herestraat 49, 3000, Leuven, Belgium.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>(1179620N)</GrantID><Agency>Fonds Wetenschappelijk Onderzoek</Agency><Country>International</Country></Grant><Grant><GrantID>..</GrantID><Agency>Fonds Wetenschappelijk Onderzoek</Agency><Country>International</Country></Grant><Grant><GrantID>...</GrantID><Agency>Fonds Wetenschappelijk Onderzoek</Agency><Country>International</Country></Grant><Grant><GrantID>...</GrantID><Agency>KOOR</Agency><Country>International</Country></Grant><Grant><GrantID>...</GrantID><Agency>valerie perrier race</Agency><Country>International</Country></Grant><Grant><GrantID>...</GrantID><Agency>als liga</Agency><Country>International</Country></Grant><Grant><GrantID>...</GrantID><Agency>E. von Behring Chair for Neuromuscular and Neurodegenerative Disorders</Agency><Country>International</Country></Grant><Grant><GrantID>...</GrantID><Agency>KU Leuven funds "Een Hart voor ALS", "Laeversfonds voor ALS Onderzoek"</Agency><Country>International</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>04</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Eur J Nucl Med Mol Imaging</MedlineTA><NlmUniqueID>101140988</NlmUniqueID><ISSNLinking>1619-7070</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0Z5B2CJX4D</RegistryNumber><NameOfSubstance UI="D019788">Fluorodeoxyglucose F18</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019788" MajorTopicYN="Y">Fluorodeoxyglucose F18</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000072078" MajorTopicYN="N">Positron Emission Tomography Computed Tomography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ALS mimics</Keyword><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">Automated spinal cord segmentation</Keyword><Keyword MajorTopicYN="N">Brain and spinal [18F]-FDG PET-CT</Keyword><Keyword MajorTopicYN="N">Convolutional neural network</Keyword><Keyword MajorTopicYN="N">Support vector machine</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>12</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>3</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>4</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>5</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>4</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32314027</ArticleId><ArticleId IdType="doi">10.1007/s00259-020-04786-y</ArticleId><ArticleId IdType="pii">10.1007/s00259-020-04786-y</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Salameh JS, Brown RH Jr, Berry JD. Amyotrophic lateral sclerosis: review. Semin Neurol. 2015;35(4):469&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pubmed">26502769</ArticleId></ArticleIdList></Reference><Reference><Citation>Paganoni S, Macklin EA, Lee A, Murphy A, Chang J, Zipf A, et al. Diagnostic timelines and delays in diagnosing amyotrophic lateral sclerosis (ALS). Amyotroph Lateral Scler Frontotemporal Degener. 2014;15(5&#x2013;6):453&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">24981792</ArticleId><ArticleId IdType="pmc">4433003</ArticleId></ArticleIdList></Reference><Reference><Citation>Pagani M, Oberg J, De Carli F, Calvo A, Moglia C, Canosa A, et al. Metabolic spatial connectivity in amyotrophic lateral sclerosis as revealed by independent component analysis. Hum Brain Mapp. 2016;37(3):942&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">26703938</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Laere K, Vanhee A, Verschueren J, De Coster L, Driesen A, Dupont P, et al. Value of 18fluorodeoxyglucose-positron-emission tomography in amyotrophic lateral sclerosis: a prospective study. JAMA Neurol. 2014;71(5):553&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">24615479</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Weehaeghe D, Ceccarini J, Delva A, Robberecht W, Van Damme P, Van Laere K. Prospective validation of 18F-FDG brain PET discriminant analysis methods in the diagnosis of amyotrophic lateral sclerosis. J Nucl Med. 2016;57(8):1238&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">26940764</ArticleId></ArticleIdList></Reference><Reference><Citation>Wheeler-Kingshott CA, Stroman PW, Schwab JM, Bacon M, Bosma R, Brooks J, et al. The current state-of-the-art of spinal cord imaging: applications. Neuroimage. 2014;84:1082&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">23859923</ArticleId></ArticleIdList></Reference><Reference><Citation>Marini C, Cistaro A, Campi C, Calvo A, Caponnetto C, Nobili FM, et al. A PET/CT approach to spinal cord metabolism in amyotrophic lateral sclerosis. Eur J Nucl Med Mol Imaging. 2016;43(11):2061&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pubmed">27421971</ArticleId><ArticleId IdType="pmc">5007279</ArticleId></ArticleIdList></Reference><Reference><Citation>Branco LM, De Albuquerque M, De Andrade HM, Bergo FP, Nucci A, Franca MC Jr. Spinal cord atrophy correlates with disease duration and severity in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2014;15(1&#x2013;2):93&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">24219347</ArticleId></ArticleIdList></Reference><Reference><Citation>El Mendili MM, Cohen-Adad J, Pelegrini-Issac M, Rossignol S, Morizot-Koutlidis R, Marchand-Pauvert V, et al. Multi-parametric spinal cord MRI as potential progression marker in amyotrophic lateral sclerosis. PLoS One. 2014;9(4):e95516.</Citation><ArticleIdList><ArticleId IdType="pubmed">24755826</ArticleId><ArticleId IdType="pmc">3995720</ArticleId></ArticleIdList></Reference><Reference><Citation>Grolez G, Kyheng M, Lopes R, Moreau C, Timmerman K, Auger F, et al. MRI of the cervical spinal cord predicts respiratory dysfunction in ALS. Sci Rep. 2018;8(1):1828.</Citation><ArticleIdList><ArticleId IdType="pubmed">29379040</ArticleId><ArticleId IdType="pmc">5789036</ArticleId></ArticleIdList></Reference><Reference><Citation>Costa J, Swash M, de Carvalho M. Awaji criteria for the diagnosis of amyotrophic lateral sclerosis: a systematic review. Arch Neurol. 2012;69(11):1410&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">22892641</ArticleId></ArticleIdList></Reference><Reference><Citation>Schrooten M, Smetcoren C, Robberecht W, Van Damme P. Benefit of the Awaji diagnostic algorithm for amyotrophic lateral sclerosis: a prospective study. Ann Neurol. 2011;70(1):79&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pubmed">21437935</ArticleId></ArticleIdList></Reference><Reference><Citation>Balendra R, Jones A, Jivraj N, Knights C, Ellis CM, Burman R, et al. Estimating clinical stage of amyotrophic lateral sclerosis from the ALS Functional Rating Scale. Amyotroph Lateral Scler Frontotemporal Degener. 2014;15(3&#x2013;4):279&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">24720420</ArticleId></ArticleIdList></Reference><Reference><Citation>van Weehaeghe D, Ceccarini J, Willekens SM, de Vocht J, van Damme P, van Laere K. Is there a glucose metabolic signature of spreading TDP-43 pathology in amyotrophic lateral sclerosis? Q J Nucl Med Mol Imaging. 2017.</Citation></Reference><Reference><Citation>Hearst MA. Support vector machines. IEEE Intell Syst App. 1998;13(4):18&#x2013;21.</Citation></Reference><Reference><Citation>van den Hoff J, Lougovski A, Schramm G, Maus J, Oehme L, Petr J, et al. Correction of scan time dependence of standard uptake values in oncological PET. EJNMMI Res. 2014;4(1):18.</Citation><ArticleIdList><ArticleId IdType="pubmed">24693879</ArticleId><ArticleId IdType="pmc">3992152</ArticleId></ArticleIdList></Reference><Reference><Citation>Ronneberger O, Fischer P, Brox T. U-net: convolutional networks for biomedical image segmentation. Lect Notes Comput Sc. 2015;9351:234&#x2013;41.</Citation></Reference><Reference><Citation>Srivastava N, Hinton G, Krizhevsky A, Sutskever I, Salakhutdinov R. Dropout: a simple way to prevent neural networks from overfitting. J Mach Learn Res. 2014;15:1929&#x2013;58.</Citation></Reference><Reference><Citation>De Leener B, Levy S, Dupont SM, Fonov VS, Stikov N, Collins DL, et al. SCT: spinal cord toolbox, an open-source software for processing spinal cord MRI data. Neuroimage. 2017;145:24&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">27720818</ArticleId></ArticleIdList></Reference><Reference><Citation>De Leener B, Mangeat G, Dupont S, Martin AR, Callot V, Stikov N, et al. Topologically preserving straightening of spinal cord MRI. J Magn Reson Imaging. 2017;46(4):1209&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pubmed">28130805</ArticleId></ArticleIdList></Reference><Reference><Citation>Tustison NJ, Cook PA, Klein A, Song G, Das SR, Duda JT, et al. Large-scale evaluation of ANTs and FreeSurfer cortical thickness measurements. Neuroimage. 2014;99:166&#x2013;79.</Citation><ArticleIdList><ArticleId IdType="pubmed">24879923</ArticleId></ArticleIdList></Reference><Reference><Citation>Avants BB, Epstein CL, Grossman M, Gee JC. Symmetric diffeomorphic image registration with cross-correlation: evaluating automated labeling of elderly and neurodegenerative brain. Med Image Anal. 2008;12(1):26&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">17659998</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai TH, Liu RS, Yang BH, Wang PS, Lin KP, Lee YC, et al. Cerebral involvement in spinal and bulbar muscular atrophy (Kennedy&#x2019;s disease): a pilot study of PET. J Neurol Sci. 2013;335(1&#x2013;2):139&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">24120273</ArticleId></ArticleIdList></Reference><Reference><Citation>Pedersen BK. Physical activity and muscle-brain crosstalk. Nat Rev Endocrinol. 2019;15(7):383&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">30837717</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark BC, Mahato NK, Nakazawa M, Law TD, Thomas JS. The power of the mind: the cortex as a critical determinant of muscle strength/weakness. J Neurophysiol. 2014;112(12):3219&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pubmed">25274345</ArticleId><ArticleId IdType="pmc">4269707</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimada H, Ishii K, Ishiwata K, Oda K, Suzukawa M, Makizako H, et al. Gait adaptability and brain activity during unaccustomed treadmill walking in healthy elderly females. Gait Posture. 2013;38(2):203&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">23266043</ArticleId></ArticleIdList></Reference><Reference><Citation>Tashiro M, Itoh M, Fujimoto T, Fujiwara T, Ota H, Kubota K, et al. 18F-FDG PET mapping of regional brain activity in runners. J Sports Med Phys Fitness. 2001;41(1):11&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">11317143</ArticleId></ArticleIdList></Reference><Reference><Citation>Watson N, Ji X, Yasuhara T, Date I, Kaneko Y, Tajiri N, et al. No pain, no gain: lack of exercise obstructs neurogenesis. Cell Transplant. 2015;24(4):591&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">25806858</ArticleId></ArticleIdList></Reference><Reference><Citation>Marini C, Morbelli S, Cistaro A, Campi C, Caponnetto C, Bauckneht M, et al. Interplay between spinal cord and cerebral cortex metabolism in amyotrophic lateral sclerosis. Brain. 2018;141(8):2272&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">30730551</ArticleId><ArticleId IdType="pmc">6061793</ArticleId></ArticleIdList></Reference><Reference><Citation>Cistaro A, Valentini MC, Chio A, Nobili F, Calvo A, Moglia C, et al. Brain hypermetabolism in amyotrophic lateral sclerosis: a FDG PET study in ALS of spinal and bulbar onset. Eur J Nucl Med Mol Imaging. 2012;39(2):251&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">22089661</ArticleId></ArticleIdList></Reference><Reference><Citation>Brettschneider J, Del Tredici K, Toledo JB, Robinson JL, Irwin DJ, Grossman M, et al. Stages of pTDP-43 pathology in amyotrophic lateral sclerosis. Ann Neurol. 2013;74(1):20&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pubmed">23686809</ArticleId><ArticleId IdType="pmc">3785076</ArticleId></ArticleIdList></Reference><Reference><Citation>Feneberg E, Oeckl P, Steinacker P, Verde F, Barro C, Van Damme P, et al. Multicenter evaluation of neurofilaments in early symptom onset amyotrophic lateral sclerosis. Neurology. 2018;90(1):E22&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">29212830</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Burgh HK, Westeneng HJ, Meier JM, van Es MA, Veldink JH, Hendrikse J, et al. Cross-sectional and longitudinal assessment of the upper cervical spinal cord in motor neuron disease. Neuroimage Clin. 2019;24:101984.</Citation><ArticleIdList><ArticleId IdType="pubmed">31499409</ArticleId><ArticleId IdType="pmc">6734179</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>